Page last updated: 2024-10-31

mitoxantrone and Alopecia

mitoxantrone has been researched along with Alopecia in 28 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Alopecia: Absence of hair from areas where it is normally present.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)."9.09Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001)
"A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis."9.09A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001)
"To evaluate the efficiency of mitoxantrone in multiple sclerosis."9.08Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. ( Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997)
"In an attempt to examine the possibility of decreased toxicity in patients with advanced breast cancer who had not previously received chemotherapy, 33 women were given combination chemotherapy consisting of mitomycin C (10 mg/m2) every 6 weeks and mitoxantrone (6 mg/m2) every 3 weeks."9.06Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. ( Begin, L; Margolese, R; Panasci, L; Pollak, M; Reinke, A; Shenouda, G, 1990)
"To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks."9.06Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987)
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)."9.05A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985)
"Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days."7.69Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994)
"Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy."7.67Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985)
"1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy."7.67[Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984)
"Two phase II trials of mitoxantrone (Novantrone; dihydroxyanthracenedione) in refractory malignant lymphoma have been conducted."7.67Mitoxantrone in malignant lymphoma. ( Bryan, S; Case, D; Dukart, G; Gams, RA; Jones, S; Stein, R; Weiss, A, 1985)
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose."7.67Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985)
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed."7.67[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984)
"Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone."7.67Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985)
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i."7.67Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988)
"Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes."6.69First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999)
"Leukopenia is similar with the three drugs."6.66A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985)
"Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin."5.27An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984)
"Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity."5.27Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985)
"The applicability and efficacy of a scalp cooling system were studied in 105 breast cancer patients receiving four cycles of adjuvant chemotherapy with mitoxantrone + cyclophosphamide (NC chemotherapy)."5.10Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. ( Camerlo, J; d'Ingrado, MP; Evans, K; Genre, D; Macquart-Moulin, G; Maraninchi, D; Protière, C; Viens, P, 2002)
"A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis."5.09A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001)
"To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)."5.09Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001)
"To evaluate the efficiency of mitoxantrone in multiple sclerosis."5.08Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. ( Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997)
"To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks."5.06Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987)
"In an attempt to examine the possibility of decreased toxicity in patients with advanced breast cancer who had not previously received chemotherapy, 33 women were given combination chemotherapy consisting of mitomycin C (10 mg/m2) every 6 weeks and mitoxantrone (6 mg/m2) every 3 weeks."5.06Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. ( Begin, L; Margolese, R; Panasci, L; Pollak, M; Reinke, A; Shenouda, G, 1990)
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)."5.05A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985)
"Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days."3.69Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994)
"1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy."3.67[Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984)
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i."3.67Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988)
"Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone."3.67Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985)
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose."3.67Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985)
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed."3.67[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984)
"Two phase II trials of mitoxantrone (Novantrone; dihydroxyanthracenedione) in refractory malignant lymphoma have been conducted."3.67Mitoxantrone in malignant lymphoma. ( Bryan, S; Case, D; Dukart, G; Gams, RA; Jones, S; Stein, R; Weiss, A, 1985)
"Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy."3.67Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985)
"Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes."2.69First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999)
"132 patients with advanced recurrent breast cancer were treated with four courses of mitozantrone 14 mg/m2 intravenously every 3 weeks (9 weeks)."2.67Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. ( Cantwell, BM; Carmichael, J; Dawes, P; Evans, RG; Farndon, J; Ghani, S; Harris, AL; Wilson, R, 1990)
"Leukopenia is similar with the three drugs."2.66A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985)
"To date, all available therapies for prostate cancer are plagued by adverse effects."2.41Complications of chemotherapy for prostate cancer. ( Beer, TM; Bubalo, JS, 2001)
"Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity."1.27Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985)
"Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin."1.27An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-199014 (50.00)18.7374
1990's8 (28.57)18.2507
2000's6 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhong, LY1
Li, QH1
Huang, ZL1
Lin, W1
Lu, ZS1
Weng, JY1
Wu, SJ1
Du, X1
Protière, C1
Evans, K1
Camerlo, J1
d'Ingrado, MP1
Macquart-Moulin, G1
Viens, P1
Maraninchi, D1
Genre, D1
Lenzhofer, R1
Rainer, H2
Schuster, R1
Pirker, P1
Dudczak, R1
Dittrich, C1
Moser, K1
De Jager, R1
Cappelaere, P2
Armand, JP2
Keiling, R2
Fargeot, P1
Bastit, P1
van Glabbeke, M1
Renard, J1
Earl, H1
Rubens, R2
Tominaga, T1
Kitamura, M1
Hayashi, K1
Takahashi, I1
Kosaki, G1
Arlin, ZA1
Friedland, ML1
Atamer, MA1
Swain, SM1
Honig, SF1
Edan, G1
Miller, D1
Clanet, M1
Confavreux, C1
Lyon-Caen, O1
Lubetzki, C1
Brochet, B1
Berry, I1
Rolland, Y1
Froment, JC1
Cabanis, E1
Iba-Zizen, MT1
Gandon, JM1
Lai, HM1
Moseley, I1
Sabouraud, O1
Kakolyris, S2
Kourousis, C1
Koukourakis, M1
Androulakis, N1
Vamvakas, L1
Agelaki, S2
Hatzidaki, D1
Samonis, G1
Tsiftsis, D1
Georgoulias, V2
Alexopoulos, A1
Kouroussis, C1
Malamos, N1
Kalbakis, K1
Kosmas, C1
Mavroudis, D1
Vlachonicolis, J1
Sarra, E1
Rigatos, G1
Beer, TM1
Bubalo, JS1
van de Wyngaert, FA1
Beguin, C1
D'Hooghe, MB1
Dooms, G1
Lissoir, F1
Carton, H1
Sindic, CJ1
Economopoulos, T1
Dimopoulos, MA1
Mellou, S1
Pavlidis, N1
Samantas, E1
Nicolaides, C1
Tsatalas, C1
Papadopoulos, A1
Papageogriou, E1
Papasavvas, P1
Fountzilas, G1
Delozier, T1
Vernhes, JC1
Brun, B1
Nasr, E1
Randria, G1
Feuilhade, F1
Gimonet, JF1
Le Bourgeois, JP1
Gherlinzoni, F1
Guglielmi, C1
Mazza, P1
Amadori, S1
Mandelli, F1
Tura, S1
Harris, AL1
Cantwell, BM1
Carmichael, J1
Wilson, R1
Farndon, J1
Dawes, P1
Ghani, S1
Evans, RG1
Panasci, L2
Shenouda, G1
Begin, L1
Pollak, M1
Reinke, A1
Margolese, R2
Martoni, A1
Rani, P1
Ercolino, L1
Canova, N1
Pannuti, F1
Ford, JM1
Leclerc, Y1
Meyer, P1
Ho, AD1
Ehninger, G1
Mjaaland, I1
Heidemann, E1
Seither, E1
Cowan, JD1
Osborne, CK1
Neidhart, JA1
Von Hoff, DD1
Constanzi, JJ1
Vaughn, CB1
Bennett, JM1
Byrne, P1
Desai, A1
White, C1
DeConti, R1
Vogel, C1
Krementz, E1
Muggia, F1
Doroshow, J1
Plotkin, D1
Mouridsen, HT2
Andersson, M1
Pedersen, L1
Cornbleet, M1
Stuart-Harris, R1
Smith, I1
Coleman, R1
McDonald, M1
van Oosterom, A1
Smyth, J1
Metz, R1
Delgado, M1
Prevot, G1
Misset, JL1
Grimbert, J1
Mathe, G1
Gams, RA1
Bryan, S1
Dukart, G2
Weiss, A1
Case, D1
Jones, S1
Stein, R1
Starling, KA1
Mulne, AF1
Vats, TS1
Schoch, I1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044]Phase 3408 participants (Anticipated)Interventional2016-07-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for mitoxantrone and Alopecia

ArticleYear
Complications of chemotherapy for prostate cancer.
    Seminars in urologic oncology, 2001, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Ga

2001
[Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
    Bulletin du cancer, 1991, Volume: 78, Issue:11

    Topics: Alopecia; Doxorubicin; Epirubicin; Heart; Humans; Leukopenia; Mitoxantrone; Nausea; Randomized Contr

1991

Trials

13 trials available for mitoxantrone and Alopecia

ArticleYear
Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:6

    Topics: Adolescent; Adult; Agranulocytosis; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytara

2009
Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2002, Volume: 10, Issue:7

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap

2002
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
    Journal of neurology, neurosurgery, and psychiatry, 1997, Volume: 62, Issue:2

    Topics: Adjuvants, Immunologic; Adult; Alopecia; Amenorrhea; Drug Therapy, Combination; Female; Follow-Up St

1997
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
    American journal of clinical oncology, 1999, Volume: 22, Issue:6

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas

1999
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:6

    Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast

2001
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
    Acta neurologica Belgica, 2001, Volume: 101, Issue:4

    Topics: Adult; Alopecia; Contrast Media; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans;

2001
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
    European journal of haematology, 2002, Volume: 68, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols

2002
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology.
    Seminars in oncology, 1990, Volume: 17, Issue:6 Suppl 10

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide;

1990
Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer.
    Lancet (London, England), 1990, Jan-27, Volume: 335, Issue:8683

    Topics: Adult; Aged; Alopecia; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Administration

1990
Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26, Issue:6

    Topics: Alkylating Agents; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diges

1990
Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
    Cancer treatment reports, 1987, Volume: 71, Issue:10

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr

1987
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica

1985
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide;

1985

Other Studies

13 other studies available for mitoxantrone and Alopecia

ArticleYear
[Mitoxantrone in the primary treatment of metastasizing breast cancer].
    Wiener klinische Wochenschrift, 1984, Apr-27, Volume: 96, Issue:9

    Topics: Aged; Alopecia; Anthraquinones; Brain Neoplasms; Breast Neoplasms; Drug Tolerance; Electrocardiograp

1984
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
    European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:11

    Topics: Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Carcinom

1984
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8

    Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Mi

1984
Selective alopecia with mitoxantrone.
    The New England journal of medicine, 1984, May-31, Volume: 310, Issue:22

    Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Female; Hair Color; Humans; Male; Mito

1984
Mitoxantrone, 5-FU, and leucovorin in breast cancer.
    Medical and pediatric oncology, 1994, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adm

1994
[Pilot study of chemotherapy with mitoxantrone, ifosfamide, 5-fluorouracil in metastatic cancers of the breast. Preliminary study].
    Bulletin du cancer, 1991, Volume: 78, Issue:11

    Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Fe

1991
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1988, Volume: 7, Issue:5

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph

1988
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow

1985
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
    Seminars in oncology, 1986, Volume: 13, Issue:1 Suppl 1

    Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla

1986
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Ev

1985
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph

1985
Mitoxantrone in malignant lymphoma.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Alopecia; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; Leukocyte Count; Lymphoma;

1985
Mitoxantrone in refractory acute leukemia in children: a phase I study.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Acute Disease; Adolescent; Alopecia; Anthraquinones; Antineoplastic Agents; Child; Child, Preschool;

1985